Pharmacokinetic Allometric Scaling of Oligonucleotides

被引：10
|
作者：
Mahmood, Iftekhar [1 ]
机构：
[1] US FDA, Off Blood Review & Res OBRR, Ctr Biol Evaluat & Res, Rockville, MD USA
来源：
NUCLEIC ACID THERAPEUTICS | 2011年 / 21卷 / 05期
关键词：
HUMAN DRUG CLEARANCE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE GEM-91; MODIFIED ANTISENSE OLIGONUCLEOTIDE; NECROSIS-FACTOR-ALPHA; PHASE-I TRIAL; INTRAVENOUS-INFUSION; PREDICTION; HUMANS; BCL-2; METABOLISM;
D O I：
10.1089/nat.2011.0299
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The objective of this study was to evaluate the predictive performance of interspecies scaling of oligonucleotides to predict clearance and volume of distribution at steady state in humans from animal data. The human pharmacokinetic parameters were predicted using 1, 2, or at least 3 animal species. The results of the study indicated that the pharmacokinetic parameters of oligonucleotides can be predicted with reasonable accuracy in humans when at least 3 animal species are employed. On the other hand, allometric scaling based on 1 or 2 species or fixed coefficient or fixed exponent can be erratic and unreliable. Further work should be conducted in this direction.
引用
收藏
页码：315 / 321
页数：7
相关论文
共 50 条
  • [41] ALLOMETRIC ANALYSIS OF DOXYCYCLINE PHARMACOKINETIC PARAMETERS
    RIOND, JL
    RIVIERE, JE
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1990, 13 (04) : 404 - 407
  • [42] Allometric scaling law in a simple oxygen exchanging network:: possible implications on the biological allometric scaling laws
    Santillán, M
    JOURNAL OF THEORETICAL BIOLOGY, 2003, 223 (02) : 249 - 257
  • [43] Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models
    Zhang, Lei
    Feng, Feifei
    Wang, Xiaohan
    Liang, Hao
    Yao, Xueting
    Liu, Dongyang
    PHARMACEUTICALS, 2024, 17 (03)
  • [44] Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson, Trevor N.
    Ke, Alice B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 : S83 - S93
  • [45] Population Pharmacokinetic Modeling and Allometric Scaling of IV ST-246® to Support Optimal Dosing Strategy in Humans
    Chen, Yali
    Leeds, Janet M.
    Shanthakumar, T. R.
    Honeychurch, Kady
    Hruby, Dennis
    Marier, J. F.
    Yan, Li
    Fenneteau, Frederique
    Mouksassi, Mohamad-Samer
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S81 - S82
  • [46] Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones
    Bhamidipati, RK
    Dravid, PV
    Mullangi, R
    Srinivas, NR
    XENOBIOTICA, 2004, 34 (06) : 571 - 579
  • [47] Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
    Malik, Paul R., V
    Edginton, Andrea N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (11): : 835 - 844
  • [48] Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings
    Mahmood, Iftekhar
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 327 - 346
  • [49] Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings
    Iftekhar Mahmood
    Clinical Pharmacokinetics, 2014, 53 : 327 - 346
  • [50] Application of Allometric Scaling to Nanochelator Pharmacokinetics
    Jones, Gregory
    Zeng, Lingxue
    Kim, Jonghan
    ACS OMEGA, 2023, 8 (30): : 27256 - 27263
12345